Literature DB >> 12823758

WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials.

Eleftherios C Vamvakas1.   

Abstract

BACKGROUND: An association between allogeneic blood transfusion (ABT) and mortality was reported by one team of investigators from randomized controlled trials (RCTs) comparing recipients of non-WBC-reduced versus WBC-reduced RBCs in open-heart surgery. A meta-analysis was undertaken to examine whether this finding can be generalized across clinical settings and/or transfused RBC components. STUDY DESIGN AND METHODS: RCTs reporting on adverse immunomodulatory effects of ABT between January 1992 and August 2002 were retrieved. Fourteen studies had recorded mortality as a primary or secondary outcome and met all other criteria for meta-analysis. Summary ORs of mortality in a treatment arm receiving WBC-containing allogeneic RBCs versus a control arm receiving autologous or WBC-reduced allogeneic RBCs were calculated across studies, for groups of studies in which the hypothesis of homogeneity was not rejected.
RESULTS: There was no association between ABT and mortality across 14 RCTs reporting on short-term mortality (summary OR, 1.20; 95% CI, 0.87-1.65) or across 3 RCTs reporting on long-term mortality (summary OR, 0.87; 95% CI, 0.64-1.19). In subgroup analyses, RCTs using autologous blood or conducted in abdominal or vascular surgery showed no difference in mortality, but short-term mortality differed across 3 RCTs conducted in open-heart surgery (summary OR, 2.26; 95% CI, 1.31-3.90; p < 0.05) and 7 RCTs comparing recipients of non-WBC-reduced versus WBC-reduced allogeneic RBCs filtered before storage (summary OR, 1.45; 95% CI, 1.00-2.11; p >/= 0.05).
CONCLUSIONS: An association between ABT and either short-term or long-term mortality was not detected across clinical settings and transfused RBC components, but subgroup analyses suggest that an association between WBC-containing ABT and short-term mortality may exist in open-heart surgery and in settings where WBC-reduced allogeneic RBCs filtered before storage are administered.

Entities:  

Mesh:

Year:  2003        PMID: 12823758     DOI: 10.1046/j.1537-2995.2003.00426.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

1.  Perioperative transfusion for pancreaticoduodenectomy and its impact on prognosis in resected pancreatic ductal adenocarcinoma.

Authors:  E Clark; S Connor; M A Taylor; C L Hendry; K K Madhavan; O J Garden; R W Parks
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

2.  History of blood transfusion before 1990 is associated with increased risk for cancer mortality independently of liver disease: a prospective long-term follow-up study.

Authors:  Yusuke Inoue; Yasuhiko Wada; Yutaka Motohashi; Akio Koizumi
Journal:  Environ Health Prev Med       Date:  2009-12-17       Impact factor: 3.674

3.  Effects of non-leukocyte-reduced and leukocyte-reduced packed red blood cell transfusions on oxygenation of rat spinotrapezius muscle.

Authors:  Sripriya Sundararajan; Sami C Dodhy; Roland N Pittman; Stephen J Lewis
Journal:  Microvasc Res       Date:  2013-11-02       Impact factor: 3.514

4.  Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event.

Authors:  Fiona C Warren; Keith R Abrams; Su Golder; Alex J Sutton
Journal:  BMC Med Res Methodol       Date:  2012-05-03       Impact factor: 4.615

5.  Effect of dilutional anemia that can be treated with only one unit of red blood cell transfusion on tissue oxygenation in cardiac surgery patients

Authors:  Demet Bölükbaşı; Alev Şaylan; Sema Turan; Sultan Sevim Yakın; Dilek Kazancı; Ayşegül Özgök; Hija Yazıcıoğlu
Journal:  Turk J Med Sci       Date:  2019-08-08       Impact factor: 0.973

Review 6.  To filter blood or universal leukoreduction: what is the answer?

Authors:  Marc J Shapiro
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

Review 7.  Infectious and immunologic consequences of blood transfusion.

Authors:  E Patchen Dellinger; Daniel A Anaya
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

8.  Use of leukoreduced blood does not reduce infection, organ failure, or mortality following trauma.

Authors:  Michael S Englehart; S David Cho; Melanie S Morris; Arvin C Gee; Gordon Riha; Samantha J Underwood; Jerome A Differding; Nick D Luem; Tracy T Wiesberg; Lynn K Boshkov; Martin A Schreiber
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

Review 9.  Anemia and transfusions in patients undergoing surgery for cancer.

Authors:  Randal S Weber; Nicolas Jabbour; Robert C G Martin
Journal:  Ann Surg Oncol       Date:  2007-10-18       Impact factor: 5.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.